Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Quiz|Articles|September 26, 2026
OncLive Weekly News Quiz (9/26/2026): Did You Catch the Latest RCC, CCA, Sarcoma, and Bladder Cancer News?
Author(s)OncLive Staff
Fact checked by: Riley Kandel
Key Takeaways
- ”).
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA approved belzutifan (Welireg) plus lenvatinib (Lenvima) for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) after a PD-1 or PD-L1 inhibitor. Which end point did belzutifan plus lenvatinib significantly improve in the phase LITESPARK-011 trial (NCT04586231)?
Advertisement
Related to this article
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
R. Lor Randall, MD, FACS, outlines how AI may affect oncology training, how to properly work alongside AI, and AI-patient conversations.
Results from an early-stage clinical trial found encouraging outcomes in newly diagnosed pancreatic cancer that had spread to distant organs.
Read a refresh of GI cancer FDA news from August 2026, including the approval of a RAS(ON) inhibitor in metastatic pancreatic cancer.
The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
R. Lor Randall, MD, FACS, discusses AI in musculoskeletal tumor diagnosis, surgical planning and robotics, and validation of AI tools.
The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
FDA Flashback: GI Cancer Decisions and News From August 2026
4
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
5